MMRGlobal Prevails in Biotech Assets Case With Lymphoma Research Foundation

LOS ANGELES, CA–(Marketwire – September 24, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (MMR) announced today that it has successfully opposed a Summary Judgment Motion brought by the Lymphoma Research Foundation (LRF) as part of its efforts to protect a portion of the Company’s intellectual property, which it previously disclosed on May 3, 2010.

The Company acquired the biotech assets from its reverse merger with Favrille, Inc., a San Diego biotech company, in January 2009. Over the past year, MMR identified a collection of these biotech assets, which include biotech samples that were in the possession of the Lymphoma Research Foundation. They do not include other pre-merger biotech assets, including the Company’s anti-CD20 monoclonal antibodies, results of clinical trials data, patents and other intellectual property.

According to declarations filed on behalf of MMR, the Company understands that the biotech samples could have a value as high as $1.376 million. However, based on other information currently maintained by the Company, the samples could have a far greater value, depending on the extent and depth of the clinical data collected at trial initiation, the extent and depth of the clinical data collected during patient follow-up, whether follow-up tissue samples are available, and whether accompanying whole blood or serum is available from patients from trial enrollment or during trial progression.

Robert H. Lorsch, Chairman and CEO of MMRGlobal, said, “We are pleased by this early ruling. When combined with clinical data from the Company’s vaccine research into the causes and potential treatment of B-Cell Non-Hodgkin’s Lymphoma, including data from patient follow-ups which the Company has, the value could be significant.”

The Company understands its intellectual properties may also be of value in a possible reinterpretation of the pre-merger Favrille vaccine trials and that the IP may also unlock ways to create other “custom-made” cancer vaccines and be valuable in discovering additional opportunities in cancer research. The Company hopes to enter into licensing agreements with biopharmaceutical companies, academic institutions, research organizations and others regarding the use of its assets.

About MMRGlobal, Inc.
MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements regarding MMRGlobal, Inc.’s assets including but not limited to its primary Health IT businesses, samples and data from vaccine and clinical trials, and anti-CD20 antibody assets. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the development and approval of biotechnology/biopharmaceutical product candidates and Health IT products and additional risks discussed in the Company’s filings with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to the Company (or any person acting on the Company’s behalf) are qualified by the cautionary statements in this notice. MMRGlobal, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information.

Click here to see all recent news from this company